Drugs News and Research

RSS

Advanced Molecular Blueprints Guide Development Of Next-Generation Malaria Drugs

Researchers from the Universities of Bath and Leeds (UK) have made a significant advance in the fight against malaria by uncovering a promising new potential target for drug discovery.

7 May 2026

New Non-Destructive Method Obtains Genetic Information From Living Cells

Normally, cells must be lysed for a so-called transcriptome analysis - which reveals which genes are currently being expressed - making repeated measurements on the same cells impossible.

7 May 2026

New Technique Improves Maturity of Lab-Grown Heart Cells for Research

Researchers at the University of Toronto's Institute of Biomedical Engineering have developed a new method to mature lab-grown heart cells, so they more closely resemble adult human heart tissue.

7 May 2026

AI Designs New Antibiotics That Reduce MRSA Infections In Mice

SyntheMol-RL integrates reinforcement learning for antibiotic design, producing synthesizable candidates that show efficacy against MRSA in preclinical models.

5 May 2026

Metabolic Pathway Loss Makes Cancer Cells Vulnerable to PARP Drugs

Loss of an enzyme necessary for a process called lipoylation disrupts the way cancer cells copy their DNA, increasing their vulnerability to a class of anticancer drugs known as PARP inhibitors, a study led by UT Southwestern Medical Center researchers shows.

5 May 2026

MRM Health’s Lead Candidate MH002 Granted Fast Track Designation by U.S. FDA for the Treatment of Mild-to-Moderate Ulcerative Colitis

MRM Health, a clinical-stage biopharmaceutical company developing therapeutics for immune-mediated diseases, which unlock the power of the microbiome to restore immune balance, today announced that MH002, the Company’s lead rationally designed Live Biotherapeutic Product (LBP) candidate, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of mild-to-moderate ulcerative colitis (UC).

From MRM Health NV 4 May 2026

New Pipeline Sharpens Single-Cell Profiling of CAR Immune Therapies

CERTOMICS is a Nextflow-based computational pipeline designed to identify and profile CAR-engineered immune cells using single-cell multiomics data. By integrating gene expression, immune receptor profiling, protein markers, CAR-aware references, and CAR-specific quality control, it supports more standardized analysis of adoptive cellular immunotherapies.

29 Apr 2026

Magnetic Microrobots That Could Transform Cancer Treatment

Cancer treatments and other delicate medical procedures might one day be performed using tiny microrobots that are precisely directed within the body, according to a new magnetic tool created by scientists.

29 Apr 2026

Proxygen Expands Platform Beyond Degradation to Build Next-Generation Induced Proximity Therapeutics

Proxygen, a biotechnology company pioneering the discovery of molecular glue degraders and next-generation proximity-based therapeutics, today publicly announced the expansion of its platform beyond targeted protein degradation to access a broader range of induced proximity therapeutics, while advancing two lead molecular glue degrader programs toward clinical development.

From Proxygen 29 Apr 2026

Drug Development: Development of Dextran Nanoparticles for Stabilizing Delicate Proteins

Nanoscale Research Letters, an open access journal published under Springer Open, presented a study entitled "Development of Dextran Nanoparticles for Stabilizing Delicate Proteins." In this study, a Brookhaven NanoBrook 90Plus Particle Size Analyzer was used to help develop a novel approach to stabilize and encapsulate proteins into dextran nanoparticles.

From Brookhaven Instruments 29 Apr 2026

Obesity Leaves Persistent Epigenetic Marks on Immune Cells

People who live with obesity are 'tagging' a memory of being overweight on a key part of the immune system - leaving people with ongoing risk of obesity-related conditions years after losing weight, according to a 10 year-long study published in EMBO Reports.

28 Apr 2026

Key Protein Switch Activates Leptospira Virulence and Disease Spread

During infection, pathogens must adapt quickly to the conditions to thrive inside the body. A research team at the University of Basel, Switzerland, has uncovered how a key protein switches on the machinery that enables Leptospira pathogens to survive and cause disease.

28 Apr 2026